High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease

Author:

Ebach Dawn R.1ORCID,Jester Traci W.2,Galanko Joseph A.3ORCID,Firestine Ann M.3ORCID,Ammoury Rana4ORCID,Cabrera Jose5,Bass Julie6,Minar Phillip7,Olano Kelly7,Margolis Peter7ORCID,Sandberg Kelly8ORCID,Linnville Tiffany M.9ORCID,Kaplan Jess10ORCID,Pitch Lisa11ORCID,Steiner Steven J.12ORCID,Bass Dorsey13,Moses Jonathan13ORCID,Adler Jeremy14ORCID,Gulati Ajay S.3ORCID,Wali Prateek15ORCID,Pashankar Dinesh16,Ivanova Anastasia17,Herfarth Hans18ORCID,Wohl David A.19ORCID,Benkov Keith J.20ORCID,Strople Jennifer21,Sullivan Jillian22ORCID,Tung Jeanne23,Molle-Rios Zorela24ORCID,Saeed Shehzad A.8ORCID,Bousvaros Athos25,Kappelman Michael D.3ORCID

Affiliation:

1. Division of Gastroenterology, Hepatology, Pancreatology, and Nutrition, University of Iowa, Iowa City, Iowa, USA;

2. Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA;

3. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA;

4. Department of Pediatrics, Children's Hospital of The King's Daughters, Norfolk, Virginia, USA;

5. Department of Pediatrics, Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA;

6. Department of Pediatrics, Children's Mercy Medical Center, UMKC School of Medicine, Kansas City, Missouri, USA;

7. Department of Pediatrics, Cincinnati Children's Medical Center, Cincinnati, Ohio, USA;

8. Boonshoft School of Medicine, Wright State University and Department of Medical Affairs, Dayton Children's Hospital, Dayton, Ohio, USA;

9. Department of Pediatrics, Atrium Health Levine Children's Hospital, Charlotte, North Carolina, USA;

10. Division of Pediatric Gastroenterology, Mass General Hospital for Children, Boston, Massachusetts, USA;

11. ImproveCareNow Parent Representative;

12. Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana, USA;

13. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford Medicine Children's Health, Palo Alto, California, USA;

14. Department of Pediatrics, University of Michigan—C.S. Mott Children's Hospital, Ann Arbor, Michigan, USA;

15. Karjoo Family Center for Pediatric Gastroenterology, Hepatology, and Nutrition, Upstate Golisano Children's Hospital, SUNY Upstate Medical Center, Syracuse, New York, USA;

16. Pediatric Gastroenterology and Hepatology, Yale New Haven Children's Hospital, Yale School of Medicine, New Haven, Connecticut, USA;

17. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA;

18. Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA;

19. University of North Carolina Institute of Global Health and Infectious Diseases, Chapel Hill, North Carolina, USA;

20. Division of Pediatric Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA;

21. Division of Pediatric Gastroenterology, Ann & Robert Lurie Children's Hospital, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA;

22. Children's Hospital of Vermont, University of Vermont, Burlington, Vermont, USA;

23. Oklahoma Children's Hospital, University of Oklahoma, Oklahoma City, Oklahoma, USA;

24. Nemour Children's Health, Wilmington, Delaware, USA;

25. Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.

Abstract

INTRODUCTION: Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-tumor necrosis factor (TNF) treatment. This study sought compares anti-TNF response and anti-TNF levels between pediatric patients with normal and high body mass index (BMI). METHODS: The COMBINE trial compared anti-TNF monotherapy with combination therapy with methotrexate in patients with PCD. In this secondary analysis, a comparison of time-to-treatment failure among patients with normal BMI vs BMI Z-score >1, adjusting for prescribed anti-TNF (infliximab [IFX] or adalimumab [ADA]), trial treatment assignment (combination vs monotherapy), and relevant covariates. Median anti-TNF levels across BMI category was also examined. RESULTS: Of 224 participants (162 IFX initiators and 62 ADA initiators), 111 (81%) had a normal BMI and 43 (19%) had a high BMI. High BMI was associated with treatment failure among ADA initiators (7/10 [70%] vs 12/52 [23%], hazard ratio 0.29, P = 0.007) but not IFX initiators. In addition, ADA-treated patients with a high BMI had lower ADA levels compared with those with normal BMI (median 5.8 vs 12.8 μg/mL, P = 0.02). IFX trough levels did not differ between BMI groups. DISCUSSION: Overweight and obese patients with PCD are more likely to experience ADA treatment failure than those with normal BMI. Higher BMI was associated with lower drug trough levels. Standard ADA dosing may be insufficient for overweight children with PCD. Among IFX initiators, there was no observed difference in clinical outcomes or drug levels, perhaps due to weight-based dosing and/or greater use of proactive drug monitoring.

Funder

Patient-Centered Outcomes Research Institute

Leona M. and Harry B. Helmsley Charitable Trust

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grifols

Publisher

Ovid Technologies (Wolters Kluwer Health)

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3